Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Osteosarcoma (OS) and Ewing sarcoma (ES) are primary bone cancers affecting children and young adults.
• Current multi-modal treatments offer limited survival improvement for OS and ES patients.
• Receptor tyrosine kinases (RTKs) are implicated in OS and ES, presenting a therapeutic target.

Purpose of the Study:

• To review current RTK-mediated therapies for OS and ES.
• To discuss challenges and resistance mechanisms in RTK inhibitor treatment.
• To propose strategies for overcoming resistance and improving patient outcomes.

Main Methods:

• Literature review of RTK-targeted therapies in OS and ES.
• Analysis of clinical trial data and resistance mechanisms.
• Discussion of strategies to enhance RTK inhibitor efficacy.

Main Results:

• RTK inhibitors show promise but face significant primary and acquired resistance in OS and ES.
• Clinical studies with RTK inhibitors have yielded limited or disappointing results, with exceptions like IGF-1R antibodies in ES.
• Resistance to RTK inhibitors is a major clinical challenge impacting treatment effectiveness.

Conclusions:

• Overcoming resistance to RTK inhibitors is essential for advancing OS and ES treatment.
• Novel strategies are needed to improve the efficacy of RTK-targeted therapies.
• Improved therapeutic approaches hold potential to significantly enhance survival rates for OS and ES patients.